IDENTIFICATION OF DIAGNOSTIC BIOMARKERS AND THERAPEUTIC AGENTS FOR ALS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 长期的目标是通过发现这种疾病的代谢组和蛋白质组生物标志物来研究ALS的发病机制。研究假设：1)ALS患者存在持续时间较长的生化改变，可在血浆和脑脊液中发现。2)这些生化特征是ALS独有的，不同于其他神经疾病和对照受试者。3)代谢组和蛋白质组的分析将为ALS提供生物标志物，揭示ALS的发病机制。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The long-term goal is to study the pathogenesis of ALS by discovering metabolomic and proteomic biomarkers for this disease. The study hypotheses are that: 1) There are biochemical changes in ALS patients that are long lasting and that can be picked up in the plasma and cerebrospinal fluid (CSF). 2) These biochemical signatures are unique to ALS and are distinct from those found in other neurological disorders and from control subjects. 3) Analysis of the metabolome and proteome will provide biomarkers for ALS and disclose disease mechanisms.